Transaction in Own Shares
Summary by AI BETAClose X
Haleon plc: Aggregated information - transactions in own shares
02 November 2026: Haleon plc (the “Company” or “Haleon”) today announces the purchase of 4,492,636 ordinary shares of £0.01 each in the Company (the “Shares”) to be held as treasury shares under its share buyback programme announced on 29 October 2026.
|
|
London Stock Exchange |
CBOE (UK)/BXE |
CBOE (UK)/CXE |
Aquis |
|
Date of purchase: |
29 October 2026 | |||
|
Number of Shares purchased: |
2,170,000 |
- |
- |
- |
|
Highest price paid per Share (p): |
334.00p |
- |
- |
- |
|
Lowest price paid per Share (p): |
310.60p |
- |
- |
- |
|
Volume weighted average price paid per Share (p): |
318.23p |
- |
- |
- |
|
Date of purchase: |
30 October 2026 | |||
|
Number of Shares purchased: |
2,322,636 |
- |
- |
- |
|
Highest price paid per Share (p): |
326.60p |
- |
- |
- |
|
Lowest price paid per Share (p): |
320.10p |
- |
- |
- |
|
Volume weighted average price paid per Share (p): |
322.97p |
- |
- |
- |
Following the settlement of the above, the Company's registered share capital is 8,808,341,409 ordinary shares of £0.01 each, of which 16,238,543 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,792,102,866 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
http://www.rns-pdf.londonstockexchange.com/rns/3013B_1-2026-11-1.pdf
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
Enquiries
|
Investors |
Media
| ||
|
Jo Russell |
+44 7787 392441 |
Zoë Bird |
+44 7736 746167 |
|
Rakesh Patel |
+44 7552 484646 |
Victoria Durman |
+44 7894 505730 |
|
|
Email: corporate.media@haleon.com | ||
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 27 minutes ago Inchcape
- 47 minutes ago Elementis
- 1 hour ago Taylor Maritime Investments Limited NPV
- 1 hour ago Derwent London
- 1 hour ago Elementis